Report Phase 3 tofersen data in SOD1-ALS patients
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 24 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- October 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“followed by Phase 3 tofersen data in patients with SOD1-ALS in the second half”
What we found
Evidence strength A What the grades mean
Filings state Phase 3 VALOR data on tofersen in SOD1-ALS were reported in October 2021, within the second-half 2021 window. Biogen is named as the reporting party in the October 2021 disclosure.
-
A Ionis Pharmaceuticals Inc. 10-K filed 2022-02-25
“For example, in October 2021, Biogen reported that tofersen did not meet the primary clinical endpoint in the Phase 3 VALOR study” ✓ confirmed on the page
-
A Ionis Pharmaceuticals Inc. 10-K filed 2022-02-25
“In 2021, we also reported data from the Phase 3 VALOR study of tofersen in patients with SOD1-ALS.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Phase 3 tofersen data in SOD1-ALS patients
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Ionis Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-IONS-024302 · Corrections policy